tiprankstipranks
Trending News
More News >
Protalix Biotherapeutics (PLX)
:PLX
Advertisement

Protalix (PLX) AI Stock Analysis

Compare
882 Followers

Top Page

PLX

Protalix

(NYSE MKT:PLX)

Select Model
Select Model
Select Model
Neutral 68 (OpenAI - 4o)
Rating:68Neutral
Price Target:
$2.00
▼(-2.91% Downside)
Protalix's overall stock score reflects strong earnings growth and promising product developments, offset by high leverage and inconsistent revenue growth. The recent CFO appointment and technical indicators suggest potential for future improvement.
Positive Factors
Revenue Growth
The significant revenue growth indicates strong market demand for Protalix's products, particularly Elfabrio, enhancing its financial stability and market position.
Product Pipeline Development
Advancements in the product pipeline, such as PRX-115, suggest potential for future revenue streams and market expansion, strengthening Protalix's competitive edge.
Leadership Change
The appointment of an experienced CFO is expected to enhance Protalix's financial strategy and operational execution, supporting long-term growth objectives.
Negative Factors
Inconsistent Revenue Growth
Fluctuating revenue growth can hinder strategic planning and financial forecasting, posing challenges to sustained business expansion and stability.
High Leverage
High leverage can limit financial flexibility and increase risk, potentially impacting Protalix's ability to invest in growth opportunities and manage economic downturns.
Increased R&D Expenses
While essential for innovation, rising R&D costs can pressure margins and cash flow, necessitating careful management to ensure financial sustainability.

Protalix (PLX) vs. SPDR S&P 500 ETF (SPY)

Protalix Business Overview & Revenue Model

Company DescriptionProtalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
How the Company Makes MoneyProtalix generates revenue primarily through the sale of its pharmaceutical products, particularly Elelyso, which is marketed in collaboration with Pfizer. The company also explores additional revenue streams through licensing agreements for its technologies and products, potential royalties from partners, and government grants for research and development. Key partnerships, such as those with Pfizer for distribution and marketing, significantly contribute to its earnings, while ongoing clinical trials and product development efforts aim to expand its portfolio and market presence.

Protalix Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 17, 2025
Earnings Call Sentiment Positive
The earnings call highlighted Protalix's significant revenue growth and promising developments in their product pipeline, particularly with Elfabrio and PRX-115. However, challenges such as decreased sales in certain regions, increased R&D expenses, and financial and tax expense increases were noted. Despite these challenges, the overall outlook remains positive due to strong partnerships and market potential.
Q2-2025 Updates
Positive Updates
Significant Revenue Increase
Protalix experienced a 50% increase in revenues from selling goods in the first half of 2025 compared to the same period last year, driven primarily by sales of Elfabrio to Chiesi.
Elfabrio Market Potential
Elfabrio is positioned in a global market estimated at USD 2.3 billion in 2025, with expectations to reach USD 3.2 billion by 2030. Protalix anticipates royalties exceeding $100 million by 2030.
Operational Highlights
Protalix has a strong partnership with Chiesi, which has consistently increased its focus on Elfabrio with substantial investments in medical, regulatory, and commercialization programs.
PRX-115 Development Progress
Protalix plans to initiate a Phase II study for their gout product candidate, PRX-115, in the second half of 2025, with promising results from previous studies.
Financial Performance Improvement
The company recorded revenues of $15.4 million for Q2 2025, a 16% increase compared to Q2 2024, and reported a net income of approximately $164,000 compared to a net loss of $2.2 million in Q2 2024.
Negative Updates
Decrease in Sales to Brazil and Pfizer
A decrease of $4.7 million in sales to Brazil and $1.2 million to Pfizer was reported, attributed to timing differences.
Increased Research and Development Expenses
R&D expenses increased by $3 million or 100% compared to Q2 2024, primarily due to preparations for the Phase II clinical trial of PRX-115.
Financial Expenses Increase
There was an increase in financial expenses due to exchange rate costs and lower interest income of bank deposits, resulting in financial expenses, net, of $0.5 million for Q2 2025.
Tax Expense Increase
Protalix recorded tax expenses of approximately $0.5 million for Q2 2025, compared to a tax benefit of approximately $0.1 million for Q2 2024.
Company Guidance
In the second quarter of 2025, Protalix BioTherapeutics reported a 50% increase in revenue from selling goods in the first half of the year, largely driven by sales of Elfabrio to Chiesi, an international biopharmaceutical group. The company recorded revenues of $15.4 million for Q2 2025, a 16% increase from the $13.3 million reported in the same period in 2024. This increase was mainly due to an $8 million rise in sales to Chiesi, although offset by decreases in sales to Brazil and Pfizer. Protalix also saw a significant 100% increase in R&D expenses, totaling $6 million, which was attributed to preparations for a Phase II clinical trial of the PRX-115 product candidate. Additionally, selling, general, and administrative expenses decreased by 26%, while the company achieved a net income of approximately $164,000 compared to a net loss of $2.2 million in the prior year. Looking forward, Protalix anticipates Elfabrio royalties to exceed $100 million by 2030, based on a projected 15% to 20% market share of the $3.2 billion Fabry disease market.

Protalix Financial Statement Overview

Summary
Protalix has shown significant improvement in profitability and cash flow generation, crucial for financial stability. However, inconsistent revenue growth and high leverage remain concerns.
Income Statement
65
Positive
The company has demonstrated a positive turnaround in profitability over the last few years. Gross profit margins have been healthy, and there was a notable improvement in net income, moving from losses to profits recently. However, revenue growth has been inconsistent with a decline in the latest period, and EBIT margins are still relatively low, indicating room for operational improvements.
Balance Sheet
55
Neutral
Protalix's balance sheet shows a significant reduction in total debt, which is a positive sign for financial health. The equity position has improved from negative to positive, enhancing the equity ratio. However, the debt-to-equity ratio is still high, indicating potential leverage risks. The company needs to continue strengthening its equity to mitigate these risks further.
Cash Flow
70
Positive
The company has shown a strong improvement in cash flow, moving from negative free cash flow to positive in the latest period. The operating cash flow to net income ratio indicates a healthy conversion of profits into cash. However, the free cash flow growth rate is volatile, suggesting potential fluctuations in cash generation capabilities.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue61.95M53.40M65.49M47.64M38.35M62.90M
Gross Profit35.64M29.08M42.51M28.05M22.00M52.02M
EBITDA10.55M6.52M12.94M-10.78M-18.94M4.45M
Net Income6.28M2.93M8.31M-14.93M-27.58M-6.52M
Balance Sheet
Total Assets78.49M73.42M84.43M55.79M73.67M67.93M
Cash, Cash Equivalents and Short-Term Investments33.40M34.83M44.56M22.18M38.98M38.55M
Total Debt5.35M5.53M26.28M33.47M33.47M64.40M
Total Liabilities28.58M30.21M50.87M66.43M79.70M94.97M
Stockholders Equity49.90M43.21M33.57M-10.64M-6.04M-27.04M
Cash Flow
Free Cash Flow-3.44M7.39M-2.47M-25.63M-11.74M-26.76M
Operating Cash Flow-2.19M8.67M-1.32M-25.00M-10.29M-26.11M
Investing Cash Flow4.26M4.22M-16.71M-5.04M18.92M-19.95M
Financing Cash Flow-7.61M-16.79M24.67M8.24M12.08M46.47M

Protalix Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.06
Price Trends
50DMA
1.64
Positive
100DMA
1.63
Positive
200DMA
1.99
Positive
Market Momentum
MACD
0.12
Negative
RSI
67.94
Neutral
STOCH
79.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLX, the sentiment is Positive. The current price of 2.06 is above the 20-day moving average (MA) of 1.81, above the 50-day MA of 1.64, and above the 200-day MA of 1.99, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 67.94 is Neutral, neither overbought nor oversold. The STOCH value of 79.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLX.

Protalix Risk Analysis

Protalix disclosed 64 risk factors in its most recent earnings report. Protalix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Protalix Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$164.25M27.8415.99%62.79%
61
Neutral
508.76M-4.20-93.19%1504.83%56.81%
46
Neutral
246.40M-1.63-415.94%-22.19%
45
Neutral
668.58M-7.3120.37%
36
Underperform
123.12M-0.7097.61%
35
Underperform
613.93M-4.41-58.02%-57.23%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PLX
Protalix
2.06
1.04
101.96%
LXRX
Lexicon Pharmaceuticals
1.40
-0.17
-10.83%
DBVT
DBV Technologies SA - American
9.16
5.66
161.71%
HURA
TuHURA Biosciences
2.46
-4.36
-63.93%
GOSS
Gossamer Bio
2.70
1.71
172.73%
TERN
Terns Pharmaceuticals
7.64
-0.70
-8.39%

Protalix Corporate Events

Private Placements and FinancingBusiness Operations and StrategyRegulatory Filings and Compliance
Protalix Amends Market Offering Agreement with H.C. Wainwright
Neutral
Aug 22, 2025

On August 22, 2025, Protalix BioTherapeutics, Inc. amended its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to offer and sell shares of its common stock through an equity offering program. This amendment aligns with the company’s new registration statement, potentially impacting its market operations and stakeholder interests.

Legal Proceedings
Protalix Lawsuit Dismissed After Bylaws Amendment
Neutral
Aug 1, 2025

On August 1, 2025, Protalix BioTherapeutics, Inc. announced the dismissal of a class action lawsuit filed by Kevin Mathew Thomas against the company and its Board of Directors. The lawsuit, filed on March 10, 2025, alleged violations in the company’s bylaws. The company denied all allegations but amended the bylaws on May 8, 2025, leading to the plaintiff agreeing that the claims were moot. Consequently, the company agreed to pay $160,000 in fees and expenses to the plaintiff’s counsel, and the case was dismissed with prejudice on July 23, 2025.

Executive/Board ChangesBusiness Operations and Strategy
Protalix Appoints New CFO to Boost Growth Strategy
Positive
Jul 21, 2025

On July 21, 2025, Protalix BioTherapeutics announced the appointment of Gilad Mamlok as the new Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. Mamlok, with three decades of experience in healthcare and technology sectors, is expected to play a crucial role in executing Protalix’s growth strategy. The transition is designed to be seamless with Rubin assisting until October 2025. This leadership change is anticipated to strengthen Protalix’s financial and operational strategies, further solidifying its position in the biopharmaceutical industry.

Executive/Board ChangesShareholder Meetings
Protalix Holds Annual Stockholders Meeting in Tel Aviv
Neutral
Jun 26, 2025

On June 26, 2025, Protalix Biotherapeutics, Inc. held its Annual Meeting of Stockholders in Tel Aviv, Israel. During the meeting, stockholders elected eight board members, approved executive compensation on a non-binding basis, and ratified the appointment of Kesselman & Kesselman as the independent accounting firm for the fiscal year ending December 31, 2025.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 10, 2025